BRISTOL, Tenn., April 15 /PRNewswire-FirstCall/ -- King Pharmaceuticals,
Inc. (NYSE: KG) reported today that the company plans to announce financial
results for the first quarter ending March 31, 2004, prior to the market open
on Thursday, May 6, 2004. Conference call information will be provided when
available via a subsequent press release.
King, headquartered in Bristol, Tennessee, is a vertically integrated
pharmaceutical company that develops, manufactures, markets, and sells branded
prescription pharmaceutical products. King, an S&P 500 Index company, seeks
to capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions, of
novel branded prescription pharmaceutical products in attractive markets and
the strategic acquisition of branded products that can benefit from focused
promotion and marketing and product life-cycle management.
This release contains forward-looking statements which reflect
management's current views of future events and operations, including, but not
limited to, statements pertaining to the anticipated date for release of the
Company's financial results for the first quarter ending March 31, 2004.
These forward-looking statements involve certain significant risks and
uncertainties, and actual results may differ materially from the forward-
looking statements. An important factor which may cause results to differ is
whether King is able to release the Company's financial results for first
quarter ending March 31, 2004, as currently planned on May 6, 2004. King does
not undertake to publicly update or revise any of its forward-looking
statements even if experience or future changes show that the indicated
results or events will not be realized.
SOURCE King Pharmaceuticals, Inc.
 back to top
Related links:
http://www.kingpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/120319.html
CONTACT:
James E. Green, Executive Vice President,
Corporate Affairs of King Pharmaceuticals, Inc., +1-423-989-8125
|
